companydata.dkResistance Oncology ApS: Financial statements 2019
CVR: 36945125
Resistance Oncology ApS (CVR 36945125) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 13,935 and a net result of DKK 9,885 compared with DKK -12,643 the year before. Equity amounted to DKK -14,912.
- Gross Profit
- 13,935 kr.
- Profit/Loss
- 9,885 kr.
- Equity
- -14,912 kr.
- Total Assets
- 7,903 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 14 t. | 10 t. | -15 t. | - |
| 2018 | - | -15 t. | -13 t. | -25 t. | - |
| 2017 | - | 51 t. | 1.1 mio. | -12 t. | 0 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2019
Resistance Oncology ApS has published its annual report for 2018. Gross profit came to DKK -14,500, and the net result was DKK -12,643.
About Resistance Oncology ApS
Resistance Oncology ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named 3B-Oncology ApS and Cortris Nordic ApS. The management consists of Nils Aage Brünner and Kasper Pasternak Jørgensen. The company is owned by TIMPCO NB ApS, Alexander Meier Holding ApS and Pasternak Holding ApS. The company has 0 employees. In 2025, the company reported a gross profit of DKK -410,610 and a net result of DKK -665,070 compared with DKK -29,048 the year before. Equity amounted to DKK 325,631.